Tropomodulin 3 promotes liver cancer progression by activating the MAPK/ERK signaling pathway.

In conclusion, TMOD3 was shown to promote liver cancer cell growth, invasion and migration through the MAPK/ERK signaling pathway, and it may serve as a candidate biomarker and therapeutic target in liver cancer. PMID: 30864730 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30864730?dopt=Abstract

Source: Oncology Reports - March 14, 2019 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research